CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 7 filers reported holding CRISPR THERAPEUTICS AG in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,224 | -82.9% | 49 | -72.5% | 0.00% | – |
| Q4 2021 | $13,000 | -60.6% | 178 | -40.3% | 0.00% | -100.0% |
| Q3 2021 | $33,000 | -46.8% | 298 | -22.8% | 0.00% | -66.7% |
| Q2 2021 | $62,000 | +17.0% | 386 | -10.4% | 0.00% | +50.0% |
| Q1 2021 | $53,000 | -17.2% | 431 | +2.9% | 0.00% | -33.3% |
| Q4 2020 | $64,000 | +255.6% | 419 | +94.9% | 0.00% | +200.0% |
| Q3 2020 | $18,000 | 0.0% | 215 | -10.0% | 0.00% | 0.0% |
| Q2 2020 | $18,000 | +80.0% | 239 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $10,000 | -33.3% | 239 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $15,000 | +66.7% | 239 | +14.4% | 0.00% | 0.0% |
| Q3 2019 | $9,000 | +125.0% | 209 | +178.7% | 0.00% | – |
| Q2 2019 | $4,000 | -99.9% | 75 | 0.0% | 0.00% | – |
| Q1 2019 | $2,679,000 | +25.0% | 75 | 0.0% | 0.00% | – |
| Q4 2018 | $2,143,000 | – | 75 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |